You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

98 Results
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
Feb 2024
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Nov 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Nov 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)
May 2019
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Updated
May 2025
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Locally Advanced Basal Cell Carcinoma
Updated
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
New
May 2025

Pages